Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UG1DA013732 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
| The Emmes Company, LLC | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Participants in MOMs will be offered the opportunity to enroll in this sub-study, which is designed to evaluate conceptual models of the mechanisms by which extended-release buprenorphine (BUP-XR), may improve mother-infant outcomes, compared to sublingual buprenorphine (BUP-SL). The additional data collected in this sub-study will be combined with data from the main MOMs trial.
It is hypothesized that: (1) the buprenorphine blood levels will vary, depending on which formulation of buprenorphine was received, (2) the variation in buprenorphine blood levels will be associated with fetal behavior (including fetal heart rate variability) (3) the variation in buprenorphine blood levels will be associated with differences in mother outcomes (including medication adherence and illicit opioid use) (4) the variation in buprenorphine blood levels and in fetal behavior will be associated with infant outcomes (including neonatal opioid withdrawal syndrome and infant development).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BUP-XR | Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly. The target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.). |
| |
| BUP-SL | Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase. The target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Buprenorphine Injection | Drug | Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cmin of buprenorphine and metabolites in plasma | A blood draw at the estimated time of minimum drug concentration ("trough") to evaluate adequacy of dose for the conceptual model. | 2 weeks post-randomization |
| Cmin of buprenorphine and metabolites in plasma | A blood draw at the estimated time of minimum drug concentration ("trough") to evaluate adequacy of dose for the conceptual model. | 4 weeks post-randomization |
| Fetal heart rate variability | This is the measure of primary interest from the fetal evaluation (non-stress test and biophysical profile). | Estimated gestational age (EGA) approximately 36 weeks |
| Cmin of buprenorphine and metabolites in plasma | A blood draw at the estimated time of minimum drug concentration ("trough") to evaluate trough-to-peak fluctuation for the conceptual model. | Estimated gestational age (EGA) approximately 36 weeks |
| Cmax of buprenorphine and metabolites in plasma | A blood draw at the estimated time of maximum drug concentration ("peak") to evaluate trough-to-peak fluctuation for the conceptual model. | Estimated gestational age (EGA) approximately 36 weeks |
| Concentration of buprenorphine and metabolites in maternal plasma | A blood draw around the time of delivery to evaluate the association between drug concentration and neonatal opioid withdrawal syndrome outcomes. | Delivery |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Participants in this study were recruited from the main CTN-0080 MOMs (NCT03918850) study sample.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| T. John Winhusen, PhD | University of Cincinnati | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gateway Community Services | Jacksonville | Florida | 32204 | United States | ||
| Massachusetts General Hospital HOPE Clinic |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37023858 | Derived | Kropp FB, Smid MC, Lofwall MR, Wachman EM, Martin PR, Murphy SM, Wilder CM, Winhusen TJ. Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study. J Subst Use Addict Treat. 2023 Jun;149:209030. doi: 10.1016/j.josat.2023.209030. Epub 2023 Apr 4. |
Not provided
Not provided
Data will be transmitted by the study Data and Statistics Center to the designated party for de-identification, posting, storing, and archiving on NIDA's Data Share website. Data Share is an online repository of data from studies funded by the National Institute on Drug Abuse. All de-identified individual participant data is expected to be made available.
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Dec 16, 2021 | Nov 1, 2023 |
Not provided
Not provided
Not provided
Not provided
| Buprenorphine Sublingual Product | Drug | Sublingual buprenorphine (BUP-SL), administered daily. |
|
|
| Concentration of buprenorphine and metabolites in cord plasma |
Cord blood will be collected and used to estimate fetal exposure to buprenorphine. |
| Delivery |
| Boston |
| Massachusetts |
| 02114 |
| United States |
| Boston Medical Center | Boston | Massachusetts | 02118 | United States |
| University of New Mexico Milagro Clinic | Albuquerque | New Mexico | 87106 | United States |
| University of Cincinnati Health Perinatal Addictions Program | Cincinnati | Ohio | 45229 | United States |
| CODA, Inc. | Portland | Oregon | 97214 | United States |
| Pregnancy Recovery Center at Magee-Womens Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | United States |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | United States |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | United States |
| University of Utah SUPeRAD Clinic | Salt Lake City | Utah | 84108 | United States |
| Addiction Recovery Services (ARS), Swedish Medical Center | Seattle | Washington | 98107 | United States |
| Marshall Health MARC Program | Huntington | West Virginia | 25701 | United States |
| ICF_001.pdf |
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| D019966 | Substance-Related Disorders |
| D009357 | Neonatal Abstinence Syndrome |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D007232 | Infant, Newborn, Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D002047 | Buprenorphine |
| D000069479 | Buprenorphine, Naloxone Drug Combination |
| ID | Term |
|---|---|
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D009270 | Naloxone |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided